EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC

Ning Wang, Zebin Zhu, Hao Zheng, Can Qi, Xiaodong Yuan, Xuefeng Li, Zhijun Xu, Jiwei Qin, Wei Wu, Jizhou Wang, Ruipeng Song, Zhiyong Guo und 3 weitere

Health Care Science · 2026-06 · 5 (3) · 196-206

DOI: 10.1002/hcs2.70071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Care Science, online erschienen am 23.04.2026. Verfasst von Ning Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Transplantation Center, First Affiliated Hospital, School of Life Sciences and Medical Center University of Sciences & Technology of China Hefei …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Anhui Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have shown promise in downstaging hepatocellular carcinoma (HCC) for liver transplantation (LT), enabling previously ineligible patients to meet transplant criteria. However, their use raises concerns about post‐transplant acute rejection (AR) based on data lacking information regarding standardized management pathways and notably perioperative protocols, including immunosuppression protocols and monitoring.

Methods

This study evaluated 59 LT recipients divided into three groups (two control groups), including 13 ICI‐exposed patients (third group). All groups followed a standardized immunosuppression protocol and monitoring embedded into an enhanced recovery after surgery (ERAS) protocol, featuring basiliximab and steroid induction, early mammalian target of rapamycin inhibitor (mTOR) use, and reduced tacrolimus dosing.

Results

Despite varied ICI washout intervals (median 36 days), no AR episodes were observed in any group. One‐year overall survival and recurrence‐free survival were 93%/85% and 100%/85% in standard patients, and 77%/69% in ICI‐exposed patients, respectively. The most frequent complications were biliary and infectious, with no significant intergroup differences.

Conclusions

These findings suggest that in a standardized clinical pathway with structured immunosuppressive protocols, therapeutic drug monitoring, and early complication surveillance, LT can be safely performed after ICI exposure without increasing rejection risk. The study underscores the need for standardized clinical pathways and consistent reporting of immunosuppressive regimens to optimize outcomes in this emerging patient population.

Schlagwörter

Stichwörter der Autor:innen

acute rejectionenhanced recovery after liver transplantationhepatocellular carcinomaimmune checkpoint inhibitor therapyimmunosuppression protocolperioperative protocolquality managementstandardized management pathway

Autor:innen und Institutionen

  • The Transplantation Center, First Affiliated Hospital, School of Life Sciences and Medical Center University of Sciences & Technology of China Hefei China.
  • Organ Transplant Centre, The First Affiliated Hospital Sun Yat-sen University Guangzhou China.
  • Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology Guangzhou China.
  • Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation) Guangzhou China.
  • NHC Key Laboratory of Assisted Circulation (Sun Yat-sen University) Guangzhou China.
  • Research Centre of Big Data and Artificial Intelligence of Medicine The First Affiliated Hospital of Sun Yat-sen University Guangzhou China.

ORCID-Profile: Björn Nashan

Förderung

  • Anhui Department of Education

Zitieren

APA

Wang, N., Zhu, Z., Zheng, H., Qi, C., Yuan, X., Li, X., Xu, Z., Qin, J., Wu, W., Wang, J., Song, R., Guo, Z., Liu, L., Zhang, S. G., & Nashan, B. (2026). Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC. Health Care Science, 5(3), 196-206. https://doi.org/10.1002/hcs2.70071

Vancouver

Wang N, Zhu Z, Zheng H, Qi C, Yuan X, Li X, et al. Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC. Health Care Science. 2026;5(3):196-206. doi:10.1002/hcs2.70071

BibTeX
@article{Wang2026,
  author = {Wang, Ning and Zhu, Zebin and Zheng, Hao and Qi, Can and Yuan, Xiaodong and Li, Xuefeng and Xu, Zhijun and Qin, Jiwei and Wu, Wei and Wang, Jizhou and Song, Ruipeng and Guo, Zhiyong and Liu, Lianxin and Zhang, Shu-Geng and Nashan, Björn},
  title = {Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC},
  journal = {Health Care Science},
  year = {2026},
  volume = {5},
  number = {3},
  pages = {196--206},
  doi = {10.1002/hcs2.70071}
}
Kostenlos starten →